Clinical Trial Update: Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of coadministering GSK Tdap vaccine Boostrix with GSK influenza vaccine Fluarix in adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Tetanus

Drugs mentioned

• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)
• Fluarix (influenza vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Diphtheria | Phase 3 | Status: COMPLETED | Results posted: 2018-09-17